Perrigo Company PLC
PRGO15.065USD
+0.125+0.84%
Cierre 01/13, 16:00（ET）Cotizaciones retrasadas 15 min
2.07BCap. mercado
PérdidaP/E TTM
Más Datos de Perrigo Company PLC Compañía
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
Información de Perrigo Company PLC
Símbolo de cotizaciónPRGO
Nombre de la empresaPerrigo Company PLC
Fecha de salida a bolsaDec 17, 1991
Director ejecutivoLockwood-Taylor (Patrick)
Número de empleados8379
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 17
DirecciónThe Sharp Building
CiudadDUBLIN
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísIreland
Código postalD02 TY74
Teléfono3532696738451
Sitio Webhttps://www.perrigo.com/
Símbolo de cotizaciónPRGO
Fecha de salida a bolsaDec 17, 1991
Director ejecutivoLockwood-Taylor (Patrick)
Ejecutivos de Perrigo Company PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Patrick Lockwood-Taylor
Mr. Patrick Lockwood-Taylor
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.81K
+4460.00%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Independent Director
Independent Director
60.29K
+8650.00%
Mr. Eduardo Guarita Bezerra
Mr. Eduardo Guarita Bezerra
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
48.95K
+3000.00%
Mr. Robert Willis
Mr. Robert Willis
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
41.94K
+1488.00%
Mr. Bradley A. (Brad) Alford
Mr. Bradley A. (Brad) Alford
Independent Director
Independent Director
41.16K
+5150.00%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
31.84K
+5150.00%
Ms. Adriana (Andi) Karaboutis
Ms. Adriana (Andi) Karaboutis
Independent Director
Independent Director
27.63K
+5150.00%
Mr. Orlando D. Ashford
Mr. Orlando D. Ashford
Independent Chairman of the Board
Independent Chairman of the Board
22.17K
+6437.00%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
10.56K
+5150.00%
Ms. Julia M. Brown
Ms. Julia M. Brown
Independent Director
Independent Director
8.03K
+5150.00%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Patrick Lockwood-Taylor
Mr. Patrick Lockwood-Taylor
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.81K
+4460.00%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Independent Director
Independent Director
60.29K
+8650.00%
Mr. Eduardo Guarita Bezerra
Mr. Eduardo Guarita Bezerra
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
48.95K
+3000.00%
Mr. Robert Willis
Mr. Robert Willis
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
41.94K
+1488.00%
Mr. Bradley A. (Brad) Alford
Mr. Bradley A. (Brad) Alford
Independent Director
Independent Director
41.16K
+5150.00%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
31.84K
+5150.00%
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Upper respiratory
182.00M
17.44%
Pain and sleep-aids
169.20M
16.22%
Skincare and personal hygiene
150.60M
14.43%
Healthy lifestyle
133.80M
12.82%
Digestive health
116.10M
11.13%
Otro
291.60M
27.95%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
635.30M
60.89%
Europe
384.00M
36.81%
All other countries
24.00M
2.30%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Upper respiratory
182.00M
17.44%
Pain and sleep-aids
169.20M
16.22%
Skincare and personal hygiene
150.60M
14.43%
Healthy lifestyle
133.80M
12.82%
Digestive health
116.10M
11.13%
Otro
291.60M
27.95%
Estadísticas de accionistas
Actualizado: jue., 8 de ene
Actualizado: jue., 8 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
T. Rowe Price Associates, Inc.
12.20%
The Vanguard Group, Inc.
10.04%
BlackRock Institutional Trust Company, N.A.
8.70%
Dimensional Fund Advisors, L.P.
5.59%
State Street Investment Management (US)
5.02%
Otro
58.46%
Accionistas
Accionistas
Proporción
T. Rowe Price Associates, Inc.
12.20%
The Vanguard Group, Inc.
10.04%
BlackRock Institutional Trust Company, N.A.
8.70%
Dimensional Fund Advisors, L.P.
5.59%
State Street Investment Management (US)
5.02%
Otro
58.46%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
64.13%
Investment Advisor/Hedge Fund
37.62%
Hedge Fund
5.32%
Research Firm
2.06%
Pension Fund
1.58%
Sovereign Wealth Fund
1.12%
Bank and Trust
0.47%
Individual Investor
0.44%
Insurance Company
0.06%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
757
155.20M
112.77%
-15.97M
2025Q3
771
148.06M
107.58%
-20.94M
2025Q2
791
145.85M
106.01%
-21.49M
2025Q1
812
142.34M
103.61%
-25.15M
2024Q4
806
140.28M
102.80%
-22.73M
2024Q3
798
138.34M
101.41%
-20.68M
2024Q2
800
136.29M
99.93%
-16.34M
2024Q1
799
135.97M
99.77%
-20.56M
2023Q4
809
135.31M
99.86%
-23.17M
2023Q3
797
133.80M
98.82%
-17.47M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
T. Rowe Price Associates, Inc.
16.79M
12.2%
+2.36M
+16.34%
Sep 30, 2025
The Vanguard Group, Inc.
13.82M
10.04%
-144.87K
-1.04%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
11.97M
8.7%
+209.84K
+1.78%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
7.70M
5.59%
+181.83K
+2.42%
Sep 30, 2025
State Street Investment Management (US)
6.90M
5.02%
-437.33K
-5.96%
Sep 30, 2025
Neuberger Berman, LLC
5.73M
4.16%
+2.02M
+54.36%
Sep 30, 2025
Cooke & Bieler, L.P.
3.68M
2.67%
+381.29K
+11.56%
Sep 30, 2025
Sound Shore Management, Inc.
3.65M
2.65%
+363.33K
+11.05%
Sep 30, 2025
Thompson, Siegel & Walmsley LLC
3.63M
2.64%
+1.30M
+56.12%
Sep 30, 2025
DePrince, Race & Zollo, Inc.
3.54M
2.57%
-1.03M
-22.50%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Sound Equity Dividend Income ETF
3.3%
State Street SPDR S&P Pharmaceuticals ETF
2.44%
Invesco Pharmaceuticals ETF
2.34%
AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF
1.54%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.35%
ProShares S&P MidCap 400 Dividend Aristocrats ETF
1.32%
First Trust Health Care Alphadex Fund
1.22%
Invesco S&P MidCap 400 Pure Value ETF
1.19%
Invesco High Yield Equity Dividend Achievers ETF
1.11%
iShares U.S. Pharmaceuticals ETF
1.05%
Ver más
Sound Equity Dividend Income ETF
Proporción3.3%
State Street SPDR S&P Pharmaceuticals ETF
Proporción2.44%
Invesco Pharmaceuticals ETF
Proporción2.34%
AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF
Proporción1.54%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción1.35%
ProShares S&P MidCap 400 Dividend Aristocrats ETF
Proporción1.32%
First Trust Health Care Alphadex Fund
Proporción1.22%
Invesco S&P MidCap 400 Pure Value ETF
Proporción1.19%
Invesco High Yield Equity Dividend Achievers ETF
Proporción1.11%
iShares U.S. Pharmaceuticals ETF
Proporción1.05%
Dividendos
Un total de
574.20M
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Oct 29, 2025
PRGO.NB Final Cash Dividend of gross USD 0.29 paid on Dec 16, 2025 going ex on Nov 28, 2025
Nov 28, 2025
Dec 16, 2025
Nov 28, 2025
Jul 30, 2025
PRGO.NB Interim Cash Dividend of gross USD 0.29 paid on Sep 16, 2025 going ex on Aug 29, 2025
Aug 29, 2025
Sep 16, 2025
Aug 29, 2025
Apr 30, 2025
PRGO.NB Interim Cash Dividend of gross USD 0.29 paid on Jun 17, 2025 going ex on May 30, 2025
May 30, 2025
Jun 17, 2025
May 30, 2025
Feb 19, 2025
PRGO.NB Interim Cash Dividend of gross USD 0.29 paid on Mar 25, 2025 going ex on Mar 07, 2025
Mar 07, 2025
Mar 25, 2025
Mar 07, 2025
Nov 01, 2024
PRGO.NB Final Cash Dividend of gross USD 0.276 paid on Dec 17, 2024 going ex on Nov 29, 2024
Nov 29, 2024
Dec 17, 2024
Nov 29, 2024
Aug 01, 2024
PRGO.NB Interim Cash Dividend of gross USD 0.276 paid on Sep 17, 2024 going ex on Aug 30, 2024
Aug 30, 2024
Sep 17, 2024
Aug 30, 2024
May 01, 2024
PRGO.NB Interim Cash Dividend of gross USD 0.276 paid on Jun 18, 2024 going ex on May 31, 2024
May 31, 2024
Jun 18, 2024
May 31, 2024
Feb 26, 2024
PRGO.NB Interim Cash Dividend of gross USD 1.1 paid on Mar 26, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Mar 26, 2024
Mar 07, 2024
Nov 03, 2023
PRGO.NB Final Cash Dividend of gross USD 0.273 paid on Dec 19, 2023 going ex on Nov 30, 2023
Dec 01, 2023
Dec 19, 2023
Nov 30, 2023
Aug 02, 2023
PRGO.NB Interim Cash Dividend of gross USD 0.273 paid on Sep 19, 2023 going ex on Aug 31, 2023
Sep 01, 2023
Sep 19, 2023
Aug 31, 2023
Ver más
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Perrigo Company PLC?
Los cinco principales accionistas de Perrigo Company PLC son:
T. Rowe Price Associates, Inc. posee 16.79M acciones, lo que representa el 12.20% del total de acciones.
The Vanguard Group, Inc. posee 13.82M acciones, lo que representa el 10.04% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 11.97M acciones, lo que representa el 8.70% del total de acciones.
Dimensional Fund Advisors, L.P. posee 7.70M acciones, lo que representa el 5.59% del total de acciones.
State Street Investment Management (US) posee 6.90M acciones, lo que representa el 5.02% del total de acciones.
T. Rowe Price Associates, Inc. posee 16.79M acciones, lo que representa el 12.20% del total de acciones.
The Vanguard Group, Inc. posee 13.82M acciones, lo que representa el 10.04% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 11.97M acciones, lo que representa el 8.70% del total de acciones.
Dimensional Fund Advisors, L.P. posee 7.70M acciones, lo que representa el 5.59% del total de acciones.
State Street Investment Management (US) posee 6.90M acciones, lo que representa el 5.02% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Perrigo Company PLC?
Los tres principales tipos de accionista de Perrigo Company PLC son:
T. Rowe Price Associates, Inc.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
T. Rowe Price Associates, Inc.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
¿Cuántas instituciones poseen acciones de Perrigo Company PLC (PRGO)?
A fecha de 2025Q4, 757 instituciones poseen acciones de Perrigo Company PLC, con un valor de mercado combinado de aproximadamente 155.20M, lo que representa el 112.77% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en 5.19%.
¿Cuál es la mayor fuente de ganancias de Perrigo Company PLC?
El FY2025Q3, el segmento empresarial Upper respiratory generó la ganancia más alta para Perrigo Company PLC, ascendiendo a 182.00M y representando el 17.44% de la ganancia total.
